Hemab Therapeutics opened lower at $38.59, compared with its previous close of $39.33. In the last trading session, the stock traded between $35.00 and $39.57. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Hemab Therapeutics is now worth
$ 115.87
Giving a profit of
$ 15.87 (15.87%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.07 (+0.17%)
Day High
$39.57
Day Low
$35.00
Day Open
$38.59
Prev Close
$39.33
Volume
3,33,654
1W Return
-12.61%
1M Return
29.29%
3M Return
-23.70%
6M Return
57.58%
1Y Return
15.87%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
4.60
PEG Ratio
-
ROE
-
ROCE
-48.31%
EPS (TTM)
-
Investment Returns
1 Week
-12.61%
1 Month
29.29%
3 Months
-23.70%
6 Months
57.58%
9 Months
15.87%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Mar 26
0.0
Jun 26
Updates
9Nov
Hemab Therapeutics launches pivotal Phase 3 trial for Glanzmann thrombasthenia
Hemab Therapeutics initiated SOLARA, its first Phase 3 trial for sutacimig. Study evaluates prophylactic treatment for Glanzmann thrombasthenia (GT). Trial includes approximately 75 participants in a single-arm design. Primary endpoint is the annualized treated bleed rate over 48 weeks. First participants scheduled to enter run-in period in Q4 2026.
3 days ago
4Nov
Hemab Therapeutics to present first sutacimig clinical data at ASH meeting
First clinical data for sutacimig in Factor VII deficiency shows >50% reduction in prothrombin time. Sutacimig demonstrated ~5x accumulation of endogenous Factor VII(a) maintained through Day 22. Preclinical data for HMB-003 show reduced severe menstrual bleeding in cynomolgus monkey model. HMB-003 exhibits week-long antifibrinolytic activity with complete return to baseline. Presentations scheduled for December 13 and 14, 2026, at the ASH Annual Meeting.
